

NEWS UPDATE

## **SPIE Photonics West Highlights Fluorescent Tracer Technology**

### **MediBeacon™ Presents a Poster Presentation at SPIE Photonics West 2013**

**(SAN FRANCISCO, February 4, 2013)** – Dr. Richard B. Dorshow, Ph.D., President, Chief Scientific Officer and Founder of MediBeacon presented a poster presentation at the 2013 Society of Photo-Optical Instrumentation Engineers (SPIE) Photonics West conference. The poster presentation entitled “Real-time point-of-care measurement of impaired renal function in a rat acute injury model employing exogenous fluorescent tracer agents” highlighted the culmination of work completed in advance of future MediBeacon clinical trials, which are designed to show the ability to detect and assess acute kidney injury and chronic kidney disease in humans.

Current clinically employed techniques lack sensitivity or are cumbersome to use. MediBeacon is developing technology that employs an exogenous fluorescent tracer agent to measure glomerular filtration rate (GFR) by noninvasively monitoring through skin. This is expected to be a substantial improvement over currently available methods.

During the conference Dr. Dorshow was quoted, “MediBeacon is progressing towards regulatory approval of a new fluorescent agent for clinical use.”

SPIE Photonics West is the largest and most influential conference (20,000 attendees, two exhibitions, 1,300 exhibiting companies, 4,500+ papers) for biophotonics, biomedical optics, translational research, industrial lasers, optoelectronics, microfabrication, optical MEMs, and more.



The abstract from the poster presentation is available at [www.medibeacon.com/news](http://www.medibeacon.com/news).

#### **About MediBeacon, LLC:**

MediBeacon LLC is a Medical Device company focused initially on kidney function monitoring in real-time. MediBeacon is housed within the Helix Center Biotech Incubator. Information regarding MediBeacon can be found at [www.medibeacon.com](http://www.medibeacon.com).

# # #